medigraphic.com

1999, Número 2

<< Anterior Siguiente >>

Enf Infec Microbiol 1999; 19 (2)


Resistencia del virus de la inmunodeficiencia humana (VIH) a medicamentos antirretrovirales

Soto RLE

Idioma: Español
Referencias bibliográficas: 34
Paginas: 64-71
Archivo PDF: 53.92 Kb.


FRAGMENTO

El tratamiento de la infección por VIH ha tenido un cambio considerable a partir del advenimiento de los inhibidores de la proteasa (IP), en vista de su gran potencia como inhibidores de la replicación viral.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280(1):78-86.

  2. Cohen J. Exploring how to get at-and eradicate-hidden HIV. Science 1998;279:1854-5.

  3. Condra JH, Emni EA. Preventing HIV drug resistance. Science & medicine 1997;4(1):1-11.

  4. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1997;70:8270-6.

  5. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.

  6. Cunningham P, Smith D, Satchell C, et al. Evidence for independent development of RT inhibitor (RTI) resistance patterns in cerebrospinal (CSF) compartment. 12th World AIDS Conference, Geneva, June 28-July 3, 1998;(Abstract 32284).

  7. Danehower SC, Mitchell CD, Gilbert CA, et al. Correlation to phenotypic resistance and clinical efficacy of abacavir in phase III pediatric study. 12th World Conference, Geneva, Switzerland, 1998[Abstract 32283].

  8. Dietrich U, Knechten H, Jaeger H, et al. High prevalence of protease resistance mutations in therapy-naive HIV-1 positive German seroconvertors irrespective of viral subtypes. 12th World Conference, Geneva, Switzerland, 1998[Abstract 41208].

  9. Fernández MS, Ruiz PG, Soto-Ramírez LE. Resistencia genotípica de VIH a indinavir y su relación con falla terapéutica en pacientes con enfermedad avanzada. XXIII Congreso Anual de la Asociación Mexicana de Infectología y Microbiología Clínica. San Luis Potosí, SLP, octubre de 1998.

  10. Harrigan PR, Montaner JS, Hogg RS, et al. Correlation of virological response with genotype and phenotype. Antiviral Therapy 1998;3(1):38.

  11. Harris M, Patenaude P, Cooperberg P, et al. Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infecction. J Infect Dis 1997;176:1388.

  12. Havlir D, Hellman C, Petropoulos J, et al. Viral rebound in the presence of indinavir without protease inhibitor resistance. 6th Conference on Retroviruse and Opportunistic Infections. Chicago, 1999: Abstract LB12.

  13. Hertogs K, Larder B, Mellors J, et al. Patterns of phenotypic and genotypic cross-resistance among protease inhibitors in over 1,000 clinical HIV-isolates. 12th World Conference, Geneva, Switzerland, 1998:[Abstract 42195].

  14. Hirsch MS, Conway B, D´Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infecction. JAMA 1998;279:1984-91.

  15. Ives KJ, Jacobsen H, Galpin SA, et al. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J Antimicrob Chemother 1997;39:771-9.

  16. Jacobsen H, Hanggi M, Ott M. In vivo resistence to a human inmunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies. J Infect Dis 1996;173:1379.

  17. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad USA 1992;89:1934-8.

  18. Kemp SD, Bloor S. Two distinct mutational pathways in HIVRT confer zidovudine/lamivudine dual resistence. International workshop on HIV drug resistance, treatment strategies and eradication. St. Petersburg, Florida, USA, June 1997, ABS 11.

  19. Lanier ER, Smiley ML, St. Clair MH, et al. Phenotypic HIV resistance in vitro correlates with viral load response to abacavir (1592, ABC) in vivo. 12th World Conference, Geneva, Switzerland, 1998:[Abstract 32289].

  20. Larden BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-9.

  21. Larden BA, Kemp SD. Multiple mutations in HIV-1 reverse trascriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-8.

  22. Larder BA, Darby G, Richman D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.

  23. Mayers D. Rational approaches to resistance: Nucleoside analogues. AIDS 1996;10(suppl 1):S9-S13.

  24. Mellors J. Review of Lago Maggiore resistance meeting. 12th World Conference, Geneva, Switzerland, 1998.

  25. Miller M, Cherrington JM, Lamy PD, Mulato AS, et al. Genotypic changes in HIV RT which develop during preveon (adefovir dipivoxil) therapy do not decrease susceptibility to PMPA. 12th World Conference, Geneva, Switzerland, 1998:[Abstract 41218].

  26. Palmer S, Shafer R, Merigan TC. New drug combinations against highly drug-resistant HIV isolates in vitro. Antiviral Therapy 1998;3(1):9.

  27. Pauwels R, Hertogs K, Peeters F, et al. Susceptibility profile (Antiviogram) of 945 clinical HIV-1 isolates to abacavir. 12th World Conference, Geneva, Switzerland, 1998:[Abstract 41226].

  28. Rawal BD, Hecht FM, Kahn J, et al. Application of novel “detuned” HIV EIA to qualify and monitor antiretroviral therapy trials in patients with early-HIV infection. 12th World Conference, Geneva, Switzerland, 1998:[Abstract 42118].

  29. Richman D. The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res 1996;29(1):31-3.

  30. Soto-Ramírez LE, Renjifo B, Marlink R, Guarner J, Río C,Essex M. Dose-dependent HIV-1 zidovudine resistance. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans,LA, EUA, 1996.

  31. Vella S. Clinical implications of resistance to antiretroviral drugs. AIDS Clinical Care 1997;9:45-7.

  32. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppresion of plasma viremia. Science 1997;278:1291-5.

  33. Yerly S, Schockmel G, Bru JP, et al. Frequency of transmission of drug-resistant variants in individuals with primary HIV-1 infection. 12th World Conference, Geneva, Switzerland, 1998:[Abstract 32280].

  34. Zalopa A, Shafer R, Warford A, et al. HIV genotypic predictors of antiviral response to saquinavir (SQV)/ritonavir (RTV) therapy in patients who have failed prior protease inhibitors (PIs): A clinical cohort study. 12th World Conference, Geneva, Switzerland, 1998:[Abstract 32287].




2020     |     www.medigraphic.com